Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015', provides an overview of the Premenstrual Dysphoric Disorder (PMDD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Premenstrual Dysphoric Disorder (PMDD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Dysphoric Disorder (PMDD) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Premenstrual Dysphoric Disorder (PMDD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Premenstrual Dysphoric Disorder (PMDD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Premenstrual Dysphoric Disorder (PMDD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Premenstrual Dysphoric Disorder (PMDD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Premenstrual Dysphoric Disorder (PMDD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Premenstrual Dysphoric Disorder (PMDD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Premenstrual Dysphoric Disorder (PMDD) Overview 6 Therapeutics Development 7 Pipeline Products for Premenstrual Dysphoric Disorder (PMDD) - Overview 7 Pipeline Products for Premenstrual Dysphoric Disorder (PMDD) - Comparative Analysis 8 Premenstrual Dysphoric Disorder (PMDD) - Therapeutics under Development by Companies 9 Premenstrual Dysphoric Disorder (PMDD) - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Premenstrual Dysphoric Disorder (PMDD) - Products under Development by Companies 12 Premenstrual Dysphoric Disorder (PMDD) - Companies Involved in Therapeutics Development 13 Azevan Pharmaceuticals, Inc. 13 Pherin Pharmaceuticals, Inc. 14 Umecrine Mood AB 15 Premenstrual Dysphoric Disorder (PMDD) - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 24 PH-80PMD - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule-1 to Antagonize GABAA Receptor for PMDD - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecule-2 to Antagonize GABAA Receptor for PMDD - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 SRX-251 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 UC-1010 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Premenstrual Dysphoric Disorder (PMDD) - Recent Pipeline Updates 31 Premenstrual Dysphoric Disorder (PMDD) - Product Development Milestones 32 Featured News & Press Releases 32 Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD) 32 May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Number of Products under Development for Premenstrual Dysphoric Disorder (PMDD), H1 2015 7 Number of Products under Development for Premenstrual Dysphoric Disorder (PMDD) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Premenstrual Dysphoric Disorder (PMDD) - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 13 Premenstrual Dysphoric Disorder (PMDD) - Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 14 Premenstrual Dysphoric Disorder (PMDD) - Pipeline by Umecrine Mood AB, H1 2015 15 Assessment by Monotherapy Products, H1 2015 16 Number of Products by Stage and Target, H1 2015 18 Number of Products by Stage and Mechanism of Action, H1 2015 20 Number of Products by Stage and Route of Administration, H1 2015 22 Number of Products by Stage and Molecule Type, H1 2015 23 Premenstrual Dysphoric Disorder (PMDD) Therapeutics - Recent Pipeline Updates, H1 2015 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.